retatrutide phase 3 results Lilly's triple agonist achieves 16.8% weight loss in trial Eli Lilly just announced striking

Circulating sDPP-4 is increased in obesity and insulin resistance but is not related to systemic metabolic inflammation

This can slow or stop breathing

Notably, it conferred a 36% relative risk reduction in new or worsening nephropathy (HR 0.64

Difficulty sleeping: The pain and discomfort when lying on the affected side can make sleeping difficult

Published online June 14, 2019 DOI: 9,260 View 94 Download 11 Web of Science 11 Crossref Abstract PDFSupplementary MaterialPubReader ePub We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM)